To solve this problem, some agents were investigated in MDS to increase the sensitivity of HMAs treatment, such as BCL-2, FLT3, and IDH inhibitor, P53 activator, etc. [5, 6]. This evidence concerns the gene FLT3 and myelodysplastic syndrome.